Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
OFX Group Limited’s half-year results reveal a sharp 78% drop in statutory net profit to $2.4 million, driven by lower fee and trading income and rising expenses. The company is advancing its New Client Platform rollout and has initiated a new share buy-back program to support growth and capital management.